|
1. Somers Kd, Winters BA, Dawson DM et al.
Chromosome abnormalities in Peyronie’s disease. J. Urol 1987; 137:672-5.
2. Ralph DJ,
Mirakian R, Pryor Jp et al. The immunological features of Peyronie’s disease. J. Urol 1996; 155:159-62.
3. Nachtsheim DA, Rearden A. peyronie’s disease is associated with an HLA class II antigen, HLA-DQ5,
Implying an autoimmune etiology. J. Urol 1996; 156:1330-4.
4. Devine CJ Jr, Somers KD, Jordan SG et al.
Proposal: Trauma as the cause of the Peyronie’s lesion. J. Urol 1997; 157:285-90.
5. Nishioka K, Kobayashi Y, Katayama I, Takjiri W.
Mast cell diffuse numbers in diffuse
sclerodermia. Arch Dermatol 1987; 123:205-8.
6. Levi-Shaffer F, Rubinchik E.
Mast-cellrole in fibrotic diseases.
Isr J Med Sci 1995; 31(7):450-453.
7. Ralph DJ, Mirakian R, Pryor JP, Bottazzo GF.
The immunological features of Peyronie’s disease. J. Urol
1996; 155:159.
8. Fries K, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willil RA, Philips RF.
Evidence of fibroblastic heterogeneity and role of fibroblast subpopulation in fibrosis. Clin Immunol Immunopath 1994; 72:283.
9. Kundig Tm, Bachmann MF, Di Paolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kuhlcke K, Hengartoer PS, Zinkernagel RM.
Fibroblasts as efficient antigen presenting cells in linphoid organs.
Science 1995; 258:1343.
10. Stewart S, Malto M, Sandberg L, Colburn K.
Increase serum levels of anti-elastin antibodies in patients with Peyronie’s disease. J. Urol
1994; 152:105.
11. Willscher MK, Cwazka WF, Novicki
DE. The association of histocolompatibilty antigens of the B-7 cross reacting group with Peyronie’s disease J. Urol 1979;122:34.
12. Deguchi T, Maeda S, Sakai S, Kuriyama M, Kawada Y, Nishiura T.
HLA-A and B antigens in patients with Peyronie’s disease. Urology 1984; 23:547.
13.
Leffell MS, Devine C Jr, Horton CE, Somers KD, Dawson D, Vande DS, Bluemick GG, Wright GI Jr.
Non association of Peyronie’s disease with HLA B7 cross-reactive
antigens. J. Urol 1982; 127:1223.
14.
Smith BH. Peyronie’s disease. Am J Clinic Pathol 1966;45:670.
15. Akkus E, Carrier K, Baba G-L, et al.
Structural alterations in the tunica albuginea of the penis: impact of Peyronie’s disease, ageing and impotence. Br J Urol
1997; 79:47-53.
16. Gelbard MK Dorey F, James K.
The natural history of Peyronie’s disease. J Urol
1990; 144:1376-8.
17. Weidner W, Schroeder-Printzen I, Weiske WH et al.
Sexual dysfunction in Peyronie’s disease: an analysis of 222 patients without previous local plaque terapy. J Urol
1997; 157:325-8.
18. Devine CJ. Introduction to the International Conference on Peyronie’s disease:
Advances in the medical therapy of Peyronie’s disease. J Urol
1997; 157:272-5.
19. Levine LA.
Advances in the medical therapy of Peyronie’s disease: a brief review. Int J Impot Res
1998; 10:123-4.
20. Carson CC.
Potassium para-aminobenzoate for the treatment of Peyronie’s disease: is it effective? Tech Urol
1997; 3:135-9.
21. Ralph DJ, Brooks MD, Bottazzo GF et al.
The treatment of Peyronie’s disease with tamoxifen. Br J Urol
1992, 70:648-51.
22. Akkus E, Carrier S, Rehman J et al.
Is colchicine effective in Peyronie’s disease? A pilot study. Urology
1994; 44:291-5.
23. Guerani A, Prigiotti G, Di Luigi
L, Gentile V. Studio preliminare sull’uso della Timopentina nella terapia dell’IPP. In: Atti S.I.A. Andrologia 1993. Ischia 1993:63-65, Acta Medica Editore.
24. Levine LA.
Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol
1997; 158:1395-9
25. Giannotti P, De Maria M.
La litotrissia extracorporea con onde d’urto nel trattamento dell’indurazio penis plastica. In: Tenaglia R, Di Silverio F, eds. Malattia di La Peyronie: Arturo 1993.
26. G. Morelli, M. De Maria, C. Selli.
Accesso basopenieno nella chirurgia del pene
curvo. Agorà 2001.
27. Ralph DJ, Mahmoud A, Pryor JP.
The Nesbit operation for Peyronie’s disease: 16 year’s experience. J Urol
1995; 154:1362-1363.
28. Levine LA, Lenting EL.
A surgical alghorithm for the treatment of Peyronie’s disease. J Urol
1997; 158:2149-2152.
29. Licht MR Lewis RW. Modified Nesbit procedure for the treatment of Peyronie’s disease: a comparative outcome analysis. J Urol
1997; 158:460-463.
30.
Lue TF, El Sakka Al. Venous patch graft for Peyronie’s disease. Part I: Technique. J Urol
1998; 160:2047-9.
31. El-Sakka Al, Rashwan HM, Lue Tf.
Venous patch graft for Peyronie’s disease. Part II: outcome analysis. J Urol
1998; 160:2050-3.
32. Montorsi F, Maga T, Salonia A et al. Evidence based long-term assessment of plaque incision and vein grafting for Peyronie’s disease. J Urol
1999; 161 (suppl); 206 (Abstr).
33. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Ioannidis E.
Corporoplasty usyng tunica albuginea free grafts for penile curvature: surgical technique and long-term results. J Urol
2002; 167:1367-1370.
34. Graziottin A.
Terapia integrata del deficit erettile funzionale. Aspetti psicosessuali, farmacologici e
riabilitativi. In: Terapia dell’impotenza erettile. Monduzzi 1994:143-149.
35. Sarramon JP, Escourrou G.
The diagnosis and management of Peyronie’s disease. Int J Impotence Res
1991; 3:69.
36. Iacono F, Barra S, De Rosa G, Boscaino A, Lotti T.
Microstructural disorders of tunica albuginea in patients affected by Peyronie’s disease with or without erection dysfunction. J Urol
1993; 150:1806-1809.
37. Akkus E, Carrier S, Baba K, HSU G-L, Padma-Nathanà H, Nunes L, Lue TF.
Structural alterations in the tunica albuginea of the penis: impact of Peyronie’s disease, ageing and impotence. Br J Urol
1997; 79:47-53.
38. Foppiani L, Manicardi G, Valenti S, Giusti M.
Sudden and unusual onset of penile plastic induration in 2 patient neurosurgically treated for pituitari
macroadenoma. Arch Ital Urol Androl 1996;
68(Suppl.5): 61-64. |
